Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-15

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goals of this project are to build an experimental tool to dissect out in vivo pancreatic beta cell mass (BCM) and beta cell function (BCF) and to assess for the first time these two determinants of beta cell functional mass (BCFxM) in obesity and in various stages of type 1 and type 2 diabetes mellitus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigating Predictive Factors of Diabetes Occurence After Duodenalpancreatectomy

NCT02175459

GLUCOSE METABOLISM DIABETES PANCREATIC ISLETS +4 more

RECRUITING

GLP-1 Receptor Targeting in Diabetic and Healthy Individuals

NCT01825148

Type 1 Diabetes

COMPLETED

The Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.

NCT00280085

Diabetes Mellitus

TERMINATED NA

Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease

NCT06725693

RECRUITING

Immune Biomarkers of Residual Beta-cell Mass in Type 1 Diabetes

NCT01747967

Type 1 Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pancreatic beta cell functional mass (BCFxM) can be loosely defined as the product of beta cell mass (BCM) multiplied by beta cell function (BCF). Current in vivo methods (e.g. hyperglycemic clamp, intravenous glucose tolerance test, oral glucose tolerance test, mixed meal tolerance test) actually assess BCFxM, not beta cell function per se. Loss of BCFxM is at the heart of the etiology and pathogenesis of both type 1 (2) and type 2 diabetes mellitus. In the former, destruction of beta cell mass by autoimmune insulitis is the the primary determinant of BCFxM loss. In the latter, beta cell mass loss is about 25-35% and keeps increasing with the duration of the disease, but an additional key role is played by the loss of beta cell function. Previous dogma held that in type 1 diabetes complete destruction of beta cells was achieved within ≈5 years from diagnosis. Recent data have challenged this concept and shown that residues of both beta cells and BCFxM (i.e. nutrient-stimulated C-peptide secretion, which is equimolar and simultaneous to insulin secretion and is a much better biomarker of BCFxM than insulin concentration) are detectable even decades after diagnosis. Exendin-4 has been already labeled with a positron emitting nuclide and made amenable to PET imaging for diagnostic purposes. Under rigorous experimental conditions, beta cell standardized uptake per volume (SUV) of the ligand could be assessed. Furthermore, current PET-CT instruments can also provide a measure of pancreatic volume BCFxM can be determined accurately by mathematical modeling of relatively simple tests, such as a mixed meal.

The investigators will assess the relative roles of beta cell mass (BCM) and beta cell function (BCF) in two polar BCFxM groups : people with long-standing type 1 diabetes (close to 0 BCFxM) and obese people with normal glucose regulation (highest expected BCFxM), i.e. the investigators will test our method in a negative control (type 1 diabetes) and in a strongly positive control (uncomplicated obesity). A group of lean controls will be studied to ascertain that their BCMs, as determined by 68GA-exendin-4 PET-CT, fall, as they should, in the intermediate range between type 1 diabetes and obesity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type1diabetes Type2diabetes Pre Diabetes Hyperinsulinism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Obese people with normal glucose regulation , patients with long standing or newly diagnosed type 1 diabetes, patients with long standing or newly diagnosed type 2 diabetes, subjects with pre-diabetes, and lean healthy age- and gender-matched controls will participate in two study sessions on two separate days:

* Session A (Endocrinology and Metabolic Diseases Unit) - Quantitation of beta cell functional mass (BCFxM) by mixed-meal test
* Session B (Nuclear Medicine Unit) - Quantitation of beta cell mass (BCM) by PET-CT scan.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Intervention Type OTHER

before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

68Ga-exendin-4

68Ga-exendin4 PET-CT scan

Intervention Type DRUG

mixed meal test

before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years; ≤ 75 years
* Both sexes
* Good health

Exclusion Criteria

* Able to understand methods, goals, and implications of the research and of delivering a free, written informed consent

* Hemoglobin \< 12 g/dl
* HbA1c \> 10%
* Pregnancy or breast-feeding
* If not in menopause, women not using effective birth control methods or not willing to undergo a pregnancy test
* History of severe psychiatric disorder or alcohol abuse
* Recent head traumas (\<6 months)
* Active neurologic diseases
* Claustrophobia
* Active malignant neoplasms
* Severe kidney and/or liver disease
* Recent (\<6 months) major adverse cardiovascular events
* Heart failure (class NYHA 3-4)
* Drugs known to affect beta cell function and/or insulin sensitivity
* Current or past treatment with GLP1R-agonists
* Intolerance to exenatide
* Endocrine diseases, other than diabetes mellitus, known to affect beta cell function and/or insulin sensitivity, except well controlled hypothyroidism or adrenal insufficiency
* COPD on day time oxygen therapy
* Any current acute disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No